fda deadline semaglutide Compounding to End FDA restricts non-approved compounded GLP-1

Gallbladder and Biliary Effects: A Murky Link GLP-1s slow gastric emptying, which helps with satietybut may also play a role in gallbladder issues

Eur J Drug Metab Pharmacokinet 33(2):101106

Poor NGF levels may disrupt neural connectivity and plasticity, hindering the formation of new memories and retrieval of stored information, which can impact daily functioning

Since effective LDL-C reduction is the most important method to improve the prognosis in HoFH, intensive treatment should be carried out, involving all available interventions, i.e., high doses of potent statins, ezetimibe, PCSK9 inhibitors, and LDL apheresis [265, 284]